Redeye remains positive to STRAX following a strong Q4 where revenues came in as expected, but operating expenses were lower than expected. For 2021, we expect a recovery for the core business from Q2 and forward. We also expect the new Health and Wellness segment to show slight y/y growth, which makes us increase our estimates on revenues while we slightly reduce our estimates on margin.